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Abstract
This study examines the effects of prostaglandin I2 (PGI2) on urokinase-type plasminogen activator (uPA) production and
wound healing by human fibroblasts. Employing fibrin autography, it was found that beraprost sodium, a stable PGI2
analog, enhanced the fibrinolytic activity in media conditioned by human fibroblasts, TIG-3-20 cells. Fibrin zymography,
ELISA, and Northern blot analysis confirmed that the enhanced activity was caused by an increase in uPA synthesis and
secretion and a decrease in type-1 plasminogen activator inhibitor. While cycloheximide and 2P,5P-dideoxyadenosine, an
adenylate cyclase inhibitor, suppressed the effect of PGI2, dibutyryl cyclic AMP increased the fibrinolytic activity and uPA
mRNA. These findings indicate that PGI2 promotes uPA production in TIG-3-20 cells via direct stimulation of the cyclic
AMP intracellular pathway. A similar effect was observed in two other fibroblast cell lines, TIG-7-20 and TIG-7-30.
Although PGI2 itself did not affect cellular proliferation, it promoted in vitro repopulation of the denuded area in a wounded
monolayer. These observations suggest that PGI2 can stimulate wound healing through the enhanced production of
uPA. z 1998 Elsevier Science B.V.
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1. Introduction
Wound healing involves extensive cellular migra-
tion and tissue remodeling during the processes of re-
epithelialization, wound contraction, and angiogene-
sis [1,2]. Interactions between the cells and extracel-
lular matrix are central to these processes and are
likely to require both degradation and rebuilding of
matrix molecules.
Plasminogen activators are serine proteases that
play a role in pericellular proteolysis, participating
in cellular migration, tumor invasion, and thrombol-
ysis [3^6]. Whereas tissue-type plasminogen activator
(tPA) has been associated primarily with ¢brinolysis,
urokinase-type plasminogen activator (uPA) is in-
volved in tissue remodeling and cellular migration
under both normal and pathological conditions, in-
cluding cancer and in£ammatory reactions. During
in vivo wound re-epithelialization, uPA has been
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shown to localize at the leading edge of migrating
keratinocytes [7^9]. Plasmin, uPA, and metallopro-
teinases may also a¡ect the release and activation
of growth factors embedded in the extracellular ma-
trix [10^12].
Prostaglandins (PGs) and other metabolites of
arachidonic acid are associated with hemostasis due
to their e¡ects on blood platelets. Platelet aggrega-
tion and secretion may be controlled by a balance
between antiaggregatory PGI2, which is produced
primarily by the blood vessels wall, and proaggrega-
tory thromboxane A2, which is produced primarily
by the platelets themselves [13,14]. Since PGI2 is a
vasodilator and thromboxane A2 a vasoconstrictor
[15], they may also in£uence blood £ow and vessel
patency through their opposing e¡ects on vascular
tone.
Interleukin-1, tumor necrosis factor, epidermal
growth factor, and platelet-derived growth factor
are known to be present during the process of wound
healing. They play important roles in the angiogene-
sis and chemotaxis of macrophages and ¢broblasts
[16,17] and promote PGI2 synthesis in endothelial
cells, macrophages, and smooth muscle cells [18^
22]. It is thus possible that PGI2 may be produced
during wound healing and a¡ect the cellular func-
tions.
In the present study, we used beraprost sodium,
a stable PGI2 analog [23,24], to assess the e¡ects
of PGI2 on ¢brinolytic activity produced by cul-
tured human ¢broblasts and the process of wound
healing.
2. Materials and methods
2.1. Materials
Beraprost sodium was kindly provided by Kaken
(Kyoto, Japan). Dulbecco’s modi¢ed Eagle’s medium
(DMEM), penicillin, streptomycin, and amphotericin
B were purchased from Gibco (Grand Island, NY).
Fetal bovine serum was purchased from Equitech-
Bio (Ingram, TX). Dibutyryl cAMP (DBcAMP), cy-
cloheximide, 2P,5P-dideoxyadenosine (DDA), and ac-
tinomycin D were purchased from American Diag-
nostica (Greenwich, CT).
Human uPA probe was prepared as described pre-
viously [25]. The uPA gene fragment (from +5433 to
+6148 in exon XI) was ¢rst ampli¢ed by the PCR,
and the resulting product was employed as a tem-
plate for a second PCR. The ¢nal product showed
a single 0.7-kb band in agarose gel and was used as
the uPA probe. Glyceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) cDNA probe was purchased
from Clontech (Palo Alto, CA).
2.2. Cell cultures
The Japanese Cancer Research Resources Bank
provided the human embryonic lung ¢broblast cell
lines, TIG-3-20, TIG-7-20, and TIG-7-30. These
cells were cultured to con£uence in either 12-well
microtiter plates or 50-mm Petri dishes containing
DMEM supplemented with 10% fetal bovine serum,
penicillin (100 U/ml), and streptomycin (100 Wg/ml)
at 37‡C under 5% CO2 and 95% humidity. After
incubation with various reagents, the conditioned
media were collected and stored at 370‡C until being
assayed.
2.3. Fibrin autography
The gross ¢brinolytic activity in the conditioned
media of human ¢broblasts was assayed employing
¢brin gel plates containing 5 mg/ml bovine ¢brinogen
(Miles, Kankakee, IL), and 1 U/ml bovine thrombin
(Mochida Pharmaceutical, Tokyo, Japan). After
being loaded with 30 Wl of each sample, the ¢brin
plate was allowed to develop at 37‡C.
2.4. Fibrin zymography
Following harvesting of the conditioned media, we
performed SDS-polyacrylamide gel electrophoresis
using 10% acrylamide gels according to the proce-
dure of Laemmli [26]. Human high molecular weight
uPA (American Diagnostica, Greenwich, CT) and
single chain tPA (American Diagnostica, Greenwich,
CT) were run in parallel as standards. After electro-
phoresis, the SDS gels were soaked in 2.5% Triton X-
100 for 1 h to remove the SDS. The gels were then
applied to the surface of a ¢brin agar indicator gel
containing 1.0% agarose, 20 Wg/ml plasminogen, 1 U/
ml thrombin, and 4 mg/ml ¢brinogen, and allowed to
develop at 37‡C.
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2.5. Measurement of uPA and PAI-1 antigen levels
The antigen levels of uPA and type-1 plasminogen
activator inhibitor (PAI-1) in the conditioned media
were measured by ELISA (TintElize uPA and PAI-1
Kit, Biopool Meditech, Ventura, CA) according to
the manufacturer’s instructions.
2.6. RNA isolation and Northern blot analysis for
uPA mRNA
The total RNA was isolated from TIG-3-20 cells
after treatment with guanidinium isothiocyanate^sar-
cosyl solution followed by phenol extraction and
ethanol precipitation. For Northern blot analysis,
5 Wg RNA per lane was electrophoresed through
1% formaldehyde agarose gels and then transferred
to a nylon membrane (Amersham, Buckinghamshire,
UK). Hybridization was performed employing a
Gene Images Random Prime Labeling and Detection
System (Amersham, South Clearbrook, IL) accord-
ing to the manufacturer’s instructions. Hybridization
was carried out using a £uorescein-labeled uPA
probe. Following incubation overnight at 65‡C, the
membrane was washed in 1USSC^0.1% SDS at 65‡C
followed by a second wash in 0.1USSC^0.1% SDS at
65‡C. The membrane was then blocked and incu-
bated with an anti-£uorescein alkaline phosphatase
conjugate. After washing o¡ the excess conjugate, the
membrane was used to catalyze light production
through the enzymatic decomposition of a stabilized
dioxetane substrate. The membrane was subse-
quently utilized for autography. After removing the
uPA probe, the membrane was rehybridized employ-
ing a GAPDH probe under the same experimental
conditions. The relative levels of mRNA signals on
the autoradiograms were quanti¢ed by image analy-
sis (BioMax 1D Image Analysis, Eastman Kodak,
Rochester, NY), and the results were expressed as
the ratio of mRNA to GAPDH mRNA.
2.7. Proliferation assay
Approximately the same numbers of TIG-3-20
cells were seeded per well into a 96-well, £at-bottom,
microtiter plate and cultured in a standard medium.
After 1 day, 1.0 Wg/ml PGI2 was added to the culture
medium. Untreated cultures served as the controls.
Following reincubation for 1^2 days, the cell num-
bers were measured using a cell counting kit (Wako,
Osaka, Japan). A tetrazolium salt, 4-[3-(4-iodophen-
yl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene di-
sulfonate (WST-1) [27], was then added, bringing
the ¢nal concentration in each well to 5 mM, and
the plates were incubated for 2 h at 37‡C. The optical
density at 405 nm was determined with a microtiter
plate reader (Model 450, Bio-Rad, Hercules, CA).
2.8. Migration assay in wound healing
As a model of wound healing, wounds were pro-
duced mechanically by scraping a plastic brush
across con£uent TIG-3-20 cells [28]. After wounding,
the cultures were incubated in media containing 1.0
Wg/ml PGI2. The control culture media contained no
additives. The migration of cells into the wounded
area was observed over a 3-day period employing
phase contrast microscopy.
3. Results
3.1. E¡ect of PGI2 on ¢brinolytic activity produced by
¢broblasts
Fig. 1 shows the time course of ¢brinolytic activity
in media conditioned by TIG-3-20 cells following
incubation with 1.0 Wg/ml PGI2. After 3 h, lysis by
the PGI2-stimulated cells increased greatly, with a
pronounced di¡erence being evident between the
PGI2-stimulated cells and the control at 12 h of in-
Fig. 1. Time course of beraprost induction of ¢brinolytic activ-
ity by TIG-3-20 cells as evaluated by ¢brin autography. TIG-3-
20 cell lines were cultured to a con£uent state in 12-well micro-
titer plates. After incubation for various periods with 1.0 Wg/ml
beraprost or with DMEM alone, 30 Wl of each of the condi-
tioned media was loaded onto the ¢brin gel containing 5 mg/ml
bovine ¢brinogen, 1 U/ml bovine thrombin and 20 Wg/ml hu-
man plasminogen. After 16 h incubation at 37‡C, the lysis of
the ¢brin gel was observed.
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cubation. It was con¢rmed that TIG-3-20 cells exhib-
ited ¢brinolytic activity and that the activity was
enhanced by PGI2.
To determine whether the increased ¢brinolytic
activity was due to tPA or uPA, ¢brin zymography
was carried out (Fig. 2). After incubation with vary-
ing concentrations of PGI2 for 12 h, the conditioned
media were examined as described above. The lytic
zone corresponded to the standard marker and was
con¢rmed as uPA. This uPA activity was enhanced
by PGI2, with the maximum increase in lysis occur-
ring at a PGI2 concentration of 1.0 Wg/ml.
The uPA antigen levels were then measured by
ELISA (Fig. 3). PGI2 stimulation of uPA secretion
was detected at a concentration of 0.01 Wg/ml, with
maximum uPA secretion being evident at 1.0 Wg/ml,
where an approximately 2.5-fold increase was ob-
served. Based on these results, a PGI2 concentration
of 1.0 Wg/ml was used for subsequent experiments.
The PAI-1 antigen levels were also measured by
ELISA (Fig. 4). PGI2 stimulation of PAI-1 demon-
strated just the opposite e¡ect to that for the uPA
antigen levels. The PAI-1 antigen levels decreased at
a PGI2 concentration of 0.001 Wg/ml and were min-
imal at a concentration of 1.0 Wg/ml, where a de-
crease of approximately 70% was observed.
To evaluate the participation of cyclic AMP in
uPA stimulation by PGI2, we examined the e¡ects
of DBcAMP, a cyclic AMP analog, and DDA, an
adenylate cyclase inhibitor. After a 12-h incubation,
the conditioned media were analyzed by ¢brin zy-
mography (Fig. 5). While the ¢brinolytic activity
with DBcAMP increased to an identical level to the
PGI2-induced activity, DDA apparently suppressed
the e¡ect. These results imply that cyclic AMP plays
a role in the stimulation of uPA by PGI2.
To determine whether or not new protein synthesis
Fig. 4. Dose-dependency of beraprost induction of PAI-1 anti-
gen levels by TIG-3-20 cells. After incubation with various con-
centrations of beraprost for 12 h, the PAI-1 antigen levels in
each of the conditioned media were measured by ELISA. The
data presented are the means þ S.D. (n = 3).
Fig. 3. Dose-dependency of beraprost induction of uPA antigen
levels by TIG-3-20 cells. After incubation with various concen-
trations of beraprost for 12 h, the uPA antigen levels in each
of the conditioned media were measured by ELISA. The data
presented are the means þ S.D. (n = 3).
Fig. 2. Zymographic analysis of media conditioned by TIG-3-
20 cells in the presence of beraprost. After incubation with vari-
ous concentrations of beraprost for 12 h, each of the condi-
tioned media was observed by ¢brin zymography as described
in Section 2. t, tPA; 1, control; 2, 0.001 Wg/ml beraprost; 3,
0.01 Wg/ml beraprost; 4, 0.1 Wg/ml beraprost; 5, 1.0 Wg/ml bera-
prost; 6, 10 Wg/ml beraprost ; u, uPA.
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is required for uPA stimulation by PGI2, we exam-
ined the e¡ects of cycloheximide, an inhibitor of cel-
lular protein synthesis, and actinomycin D, an inhib-
itor of RNA synthesis. The ¢brinolytic activity in the
media conditioned by PGI2-treated cells that had
received either cycloheximide or actinomycin D was
analyzed by ¢brin zymography (Fig. 5). While the
¢brinolytic activity in the PGI2-treated cells in-
creased, the addition of either cycloheximide or acti-
nomycin D suppressed the ¢brinolytic activity to the
level of the control, suggesting that gene expression
of uPA is required for the e¡ects of PGI2 to be
observed.
We also investigated the e¡ect of PGI2 on the
¢brinolytic activity in two other human ¢broblast
cell lines, TIG-7-20 and TIG-7-30. After a 12-h in-
cubation with 1.0 Wg/ml PGI2, all conditioned media
were evaluated by ¢brin autography. The ¢brinolytic
activity increased in all PGI2-treated cells in compar-
ison with the controls (Fig. 6).
3.2. E¡ect of PGI2 on uPA mRNA level
To con¢rm PGI2 stimulation of uPA protein syn-
thesis, uPA mRNA was measured using Northern
blot analysis. mRNA reached its maximum level at
1 h and then declined (Fig. 7A). When compared
according to the ratio of mRNA to GAPDH
mRNA, the relative uPA mRNA level increased to
approximately 20-fold that of the control (Fig. 7B),
Fig. 7. Time course of beraprost induction of uPA mRNA ex-
pression in TIG-3-20 cells as evaluated by Northern blot analy-
sis. The total RNA was isolated from TIG-3-20 cells stimulated
with 1.0 Wg/ml beraprost, after incubation for various periods.
Sequentially, the RNA was electrophoresed and transferred to a
nylon membrane. Hybridization was performed with labeled
uPA probe. The membrane was analyzed as described in Sec-
tion 2. (A) Autoradiogram of membrane. (B) Ratio of uPA/
GAPDH mRNA, as determined by image analysis, with the ra-
tio for time 0 set at 1.
Fig. 6. Comparison of ¢brinolytic activity in media conditioned
by TIG-3-20, TIG-7-20 and TIG-7-30 cells treated with bera-
prost. After 12 h stimulation of TIG-3-20, TIG-7-20 and TIG-
7-30 cells with 1.0 Wg/ml beraprost, each of the conditioned me-
dia was observed by ¢brin autography.
Fig. 5. Comparative e¡ects of induction of DBcAMP, DDA,
cycloheximide, and actinomycin D on uPA secretion by TIG-3-
20 cells. After incubation with various reagents for 12 h, each
of the conditioned media was observed by ¢brin zymography.
t, tPA; 1, 250 WM DBcAMP; 2, 1.0 Wg/ml beraprost+100 WM
DDA; 3, control ; 4, 1.0 Wg/ml beraprost; 5, 1.0 Wg/ml bera-
prost+10 Wg/ml cycloheximide; 6, 1.0 Wg/ml beraprost+10 Wg/ml
actinomycin D; u, uPA.
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indicating that PGI2 promotes uPA protein synthesis
in TIG-3-20 cells.
In addition, we examined the e¡ects of cyclohex-
imide, DBcAMP, and DDA by Northern blot anal-
ysis. After a 1-h incubation of TIG-3-20 cells treated
with each reagent, the total RNA was extracted and
analyzed for uPA mRNA. When the cells were
incubated with cycloheximide, the uPA mRNA
level increased, rising even higher on treatment
with cycloheximide supplemented with PGI2 (Fig.
8). With DDA, the level dropped. When the cells
were incubated with DBcAMP, the level increased
to the same value as that for the PGI2-stimulated
cells, con¢rming the in£uence of cAMP on the uPA
mRNA levels.
Fig. 10. E¡ect of beraprost on wound healing. Con£uent TIG-3-20 cells were wounded mechanically by scraping with a plastic brush.
After incubation with or without 1.0 Wg/ml beraprost, the migration of the cells into the wounded area was observed by phase con-
trast microscopy over a period of 72 h.
Fig. 9. E¡ect of beraprost on cell proliferation. Approximately
the same numbers of TIG-3-20 cells were incubated with or
without 1.0 Wg/ml beraprost in a 96-well microtiter plate. After
reincubation periods of 1 and 2 days, the cell numbers were
measured by WST-1 assay. The optical density at 405 nm was
determined. The data presented are the means þ S.D. (n = 3).
Fig. 8. E¡ects of cycloheximide, DBcAMP, and DDA on uPA
mRNA expression in TIG-3-20 cells. The total RNA was iso-
lated from TIG-3-20 cells stimulated with various reagents for
1 h. Sequentially, the RNA was subjected to Northern blot
analysis. 1 and 5, control ; 2 and 6, 1.0 Wg/ml beraprost; 3,
10 Wg/ml cycloheximide; 4, 1.0 Wg/ml beraprost+10 Wg/ml cyclo-
heximide; 7, 200 WM DBcAMP; 8, 1.0 Wg/ml beraprost+200
WM DDA.
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3.3. E¡ect of PGI2 on cellular proliferation
To determine the e¡ect of PGI2 on TIG-3-20 cel-
lular proliferation, a PGI2 concentration of 1.0 Wg/ml
was added to TIG-3-20 cells in a non-con£uent state.
After 1^2 days, the numbers of cells were measured
employing the WST-1 Uptake Assay. When the TIG-
3-20 cultures were grown in the presence of PGI2, the
proliferation rate did not di¡er from that of the con-
trol cultures (Fig. 9), indicating that PGI2 does not
a¡ect cellular proliferation.
3.4. E¡ect of PGI2 on cellular migration during
wound healing
As outlined above, wounds were produced me-
chanically by scraping a plastic brush across con£u-
ent TIG-3-20 cells. The migration of cells into the
wounded area was monitored over a 3-day period
by phase contrast microscopy. We observed repopu-
lation of the denuded area leading to full closure of
the wound in the presence of PGI2. Over the 3-day
period, repopulation of the denuded area was stimu-
lated by the presence of PGI2 as compared with the
controls (Fig. 10). These results indicate that PGI2
can stimulate cellular migration and subsequent
wound healing.
4. Discussion
Recent studies have shown that the plasminogen^
plasmin system is involved in wound healing. Either
uPA or tPA has been detected at the leading edge of
migrating keratinocytes [7,8,29], ¢broblasts [29], mi-
crovascular endothelial cells [30], and corneal epithe-
lial cells [31]. In addition, enhanced expression of
uPA and PAI-1 mRNA has been observed in endo-
thelial cells and renal epithelial cells at the edge of
the wound [32,33]. Based on immunohistochemical
studies and in situ hybridization, uPA has been iden-
ti¢ed during in vivo experiments involving re-epithe-
lialization of mouse and human skin wounds
[9,34,35]. In addition to playing a role in proteolytic
degradation of the extracellular matrix, uPA may
also serve as a chemotaxin or a mitogen [36^38].
Further research has indicated that uPA and plasmin
may a¡ect cytokine release and activity [39,40].
Although the precise role of uPA is not fully under-
stood, accumulated evidence suggests the importance
of uPA in wound healing.
To date, several interactions between PGs and the
¢brinolytic system have been described. PGE1 and
PGE2 increase ¢brinolytic activity by stimulating
plasminogen activator production in various cell
types including ovarian granuloma cells [41], human
foreskin ¢broblasts [42], embryonic lung ¢broblasts
[43], osteoblasts [44], and endometrial stromal cells
[45]. Although Crutchley et al. reported that PGI2
stimulated the ¢brinolytic activity in human foreskin
¢broblasts [42], they did not speci¢cally identify the
agent responsible for this increased ¢brinolytic activ-
ity.
In our study, we demonstrated that PGI2 enhances
uPA secretion and synthesis by human embryonic
¢broblasts, TIG-3-20. Since PGI2 is very unstable
with a half-life of 5^10 min in aqueous solution, we
employed the stable PGI2 analog, beraprost sodium,
which has been reported to exhibit an identical e¡ect
to PGI2 on platelet aggregation and vasodilation
[23,24]. As shown in Fig. 1, PGI2 enhanced the ¢bri-
nolytic activity in human ¢broblasts. Using ¢brin
zymography (Fig. 2) and ELISA (Fig. 3), this in-
creased activity was con¢rmed to be due to uPA.
In addition, it was demonstrated by Northern blot
analysis (Fig. 7) that PGI2 promoted uPA synthesis.
The secretion and synthesis of uPA were suppressed
by both cycloheximide and actinomycin D (Figs. 5
and 8), indicating that the e¡ect of PGI2 on uPA
expression does not require de novo protein synthe-
sis. DBcAMP, as well as PGI2, increased the ¢brino-
lytic activity in ¢broblasts, while DDA suppressed
the e¡ect of PGI2 (Figs. 5 and 8). Similar ¢ndings
were also obtained for other human ¢broblast
cell lines (Fig. 6). From these results, we conclude
that PGI2 enhances uPA synthesis in ¢broblasts via
direct stimulation of the cyclic AMP intracellular
pathway. This is consistent with the fact that PGI2
stimulates the cyclic AMP levels in human ¢broblasts
[46].
Recent studies have con¢rmed that PGE2 stimu-
lates corneal endothelial wound healing [47,48] and
bone resorption in osteosarcoma cells [49]. To our
knowledge, there has been no previous report con-
cerning the e¡ect of PGI2 on wound healing.
Although in our experiments, PGI2 promoted cellu-
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lar migration during wound healing in vitro (Fig.
10), PGI2 itself had no e¡ect on cellular proliferation
(Fig. 9). Rather, the observed cellular proliferation
may have been the result of an interaction between
the migrating cells and the extracellular matrix re-
maining after the cultures had been removed, or
could have resulted from activating growth factors
or releasing growth factors in the extracellular ma-
trix.
Wounds cause damage to limited numbers of epi-
thelial and connective tissue cells. The wounded area
immediately ¢lls with clotted blood containing ¢brin
and blood cells. Subsequently, neutrophils, endothe-
lial cells, and macrophages migrate towards the ¢brin
clot where they grow, thereby leading to wound heal-
ing. Since such cells are known to produce PGI2 by
stimulating various cytokines and growth factors
[19^22], PGI2 may be supplied to ¢broblasts during
all phases of wound healing.
Clinically, PGI2 analog is used for chronic artery
obstruction disease and is known to be e¡ective
in healing skin ulcers. Although this e¡ect is thought
to be the result of an improved peripheral cir-
culation through vasodilation, our study raises the
possibility that PGI2 may directly a¡ect wound heal-
ing by stimulating uPA production in human ¢bro-
blasts.
In addition, we have observed that the expression
of uPA receptor is enhanced in PGI2-stimulated ¢-
broblasts (data not shown). The uPA receptor is a
cell-surface protein which plays an important role in
the regulation and location of uPA-catalyzed extra-
cellular matrix degradation [50]. Our ¢ndings provide
a new insight into the possible role of PGI2 in the
regulation of pericellular proteolysis during wound
healing.
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